Page last updated: 2024-12-10
(S,S)-formoterol
Description
**(S,S)-formoterol** is a specific enantiomer of the drug **formoterol**. Let's break down what that means and why it's significant in research:
**Enantiomers**
* **Chiral molecules** are molecules that have a non-superimposable mirror image. Think of your hands – they're mirror images, but you can't make them perfectly overlap.
* **Enantiomers** are pairs of chiral molecules that are mirror images of each other.
* Drugs often exist as enantiomers.
**Formoterol**
* Formoterol is a **long-acting beta-2 adrenergic receptor agonist**. This means it relaxes the muscles in the airways, making it a key drug for treating asthma and chronic obstructive pulmonary disease (COPD).
* It's typically sold as a **racemic mixture**, meaning it contains an equal mixture of both (R,R)-formoterol and (S,S)-formoterol enantiomers.
**(S,S)-formoterol**
* **Higher potency:** Studies have shown that the (S,S)-enantiomer of formoterol is significantly more potent than the (R,R)-enantiomer. This means it's more effective at lower doses.
* **Longer duration of action:** The (S,S)-enantiomer also has a longer duration of action than the (R,R)-enantiomer.
**Importance for Research**
* **Understanding drug efficacy:** By studying (S,S)-formoterol, researchers can better understand the specific mechanisms of action of the drug and how its structure relates to its therapeutic properties. This could lead to the development of more potent and targeted therapies.
* **Development of new drugs:** The understanding gained from studying (S,S)-formoterol could be applied to the design of new drugs with improved efficacy and reduced side effects.
* **Pharmacokinetic studies:** Researchers can investigate how (S,S)-formoterol is absorbed, distributed, metabolized, and eliminated from the body. This information is crucial for optimizing drug dosage and minimizing side effects.
* **Clinical trials:** (S,S)-formoterol could be used in clinical trials to compare its effectiveness and safety to the racemic mixture of formoterol or other asthma treatments.
**In conclusion,** the study of (S,S)-formoterol is important because it allows researchers to explore the unique properties of this specific enantiomer and its potential advantages over the racemic mixture. This research could lead to advancements in asthma and COPD treatments.
formoterol : A racemate consisting of equal amounts of arformoterol (the active enantiomer) and (S,S)-formoterol (the inactive enantiomer). Its fumaric acid salt is used as a direct-acting sympathomimetic and bronchodilator for the treatment of chronic obstructive pulmonary disease (any progressive respiratory disease that makes it harder to breathe over time, such as chronic bronchitis and emphysema). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
(S,S)-formoterol : An N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide in which both of the stereocentres have S configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (24)
Synonym |
BIDD:GT0743 |
NCGC00025167-01 |
tocris-1448 |
73573-87-2 |
formoterol |
n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide |
(s,s)-formoterol |
CHEBI:63081 , |
n-{2-hydroxy-5-[(1s)-1-hydroxy-2-{[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide |
(+)-formoterol |
(s,s)-n-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formaldehyde |
SCHEMBL595410 |
AB00698470-08 |
67346-48-9 |
CHEMBL1433762 |
AB00698470_10 |
DTXSID80110070 |
sr-01000597976 |
SR-01000597976-1 |
NCGC00025167-03 |
DTXSID1023077 , |
Q27132368 |
NCGC00025167-16 |
NCGC00025167-02 |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Drug Classes (1)
Class | Description |
N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide | A phenylethanoloamine having 4-hydroxy and 3-formamido substituents on the phenyl ring and an N-(4-methoxyphenyl)propan-2-yl substituent. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (23)
Potency Measurements
Ceullar Components (1)
Bioassays (7)
Assay ID | Title | Year | Journal | Article |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6
| A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
| Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.72 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.51 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |